ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Apr 18, 2025
Dividend Increases/Decreases for the Week of April 18
Let's take a look at firms raising/lowering their dividends this week.
Apr 4, 2025
Trump Tariffs Higher than Expected; What We're Doing
The Trump tariff increases came in larger than what we were expecting, and it remains to be seen how they will flow through the global economy, as we monitor potential retaliatory tariffs from other countries. As it relates to the equity markets, we’re taking a wait and see approach at the moment as we monitor new policy changes related to trade, immigration, fiscal (tax), and regulations. In short, we’re not overreacting to the sell off as we won’t have a great handle on the tariff impact to companies for a few quarters when they report results post-tariff increases. That said, we’re expecting continued market volatility, with meaningful risk to the downside, before trade uncertainty alleviates in the coming months.
Jan 24, 2025
Johnson & Johnson Issues Fourth Quarter Results
Image Source: J&J. For the full year 2024, J&J's free cash flow came in at ~$19.8 billion, up from $18.2 billion last year. The company ended the quarter with ~$12 billion in net debt. J&J made significant pipeline progress in the quarter including RYBREVANT + LAZCLUZE overall survival data, initiation of TAR-200 submission, and the approval of investigational device exemption for its general surgery robotic system, OTTAVA. J&J issued guidance or 2025 calling for operational sales growth of 2.5%-3.5%, below the consensus forecast, and adjusted operational earnings per share growth of $10.75-$10.95, reflecting 8.7% growth at the midpoint. We like J&J, but the company does not make the cut for inclusion in any newsletter portfolio at this time.
Oct 16, 2024
Johnson & Johnson's Shares Look Fairly Valued
Image: Johnson & Johnson’s 2024 P&L guidance. Looking to all of 2024, Johnson & Johnson expects the midpoint of adjusted operational sales growth of 6%, up from its prior expectation of 5.8%. At the midpoint, diluted adjusted operational earning per share expansion is targeted at $9.91 per share down from $10.05 per share due to a negative impact from its recent acquisition of V-Wave. Our fair value estimate stands at $165 per share, about in-line with where shares are currently trading. Shares yield ~3%.
Sep 26, 2024
An Important Measure of Leverage for Dividend-Growth and Income-Oriented Shareholders, One That Is Dividend-Adjusted
As more and more investors rely on company dividends for income, dividends, in our view, have become more debt-like commitments in nature, especially from the perspective of dividend-growth or income-oriented shareholders. Years ago, we rolled out a measure of financial leverage that considers both the company’s debt and the present value of its future expected cash dividend obligations, which, in the eyes of die-hard dividend-growth or income-oriented shareholders, may be implicitly assumed to be debt-like commitments in substance. We think this leverage ratio can be used in conjunction with the Dividend Cushion ratio to gain additional insight into the dividend-paying financial health of an entity.
Aug 9, 2024
Paper: Value and Momentum Within Stocks, Too
Abstract: This paper strives to advance the field of finance in four ways: 1) it extends the theory of the “The Arithmetic of Active Management” to the investor level; 2) it addresses certain data problems of factor-based methods, namely with respect to value and book-to-market ratios, while introducing price-to-fair-value ratios in a factor-based approach; 3) it may lay the foundation for academic literature regarding the Valuentum, the value-timing, and ultra-momentum factors; and 4) it walks through the potential relative outperformance that may be harvested at the intersection of relevant, unique and compensated factors within individual stocks.
Jul 17, 2024
Johnson & Johnson Finetunes 2024 Bottom Line Guidance
Image: J&J’s shares have faced pressure since the beginning of 2023. Looking to all of 2024, J&J continues to expect adjusted operations sales growth in the range of 5.5%-6%, but it finetuned adjusted operational earnings per share to the range of $10.00-$10.10 from $10.60-$10.75 previously. The company’s improved performance was offset by the collective impact of its recent acquisitions of Shockwave Medical, Proteologix, and NM26 Bispecific Antibody. We’re not reading too much into the downward bottom-line guidance revision as J&J remains a free-cash-flow cow with a pristine AAA credit rating. Though J&J is not included in any newsletter portfolio, it’s hard not to like the company. Shares yield ~3.3% at the time of this writing.
Jul 7, 2024
Latest Report Updates
Check out the latest report updates on the website.
Jun 10, 2024
Update: Frequently Asked Questions About Valuentum Securities, Inc.
Valuentum (val∙u∙n∙tum) [val-yoo-en-tuh-m] Securities Inc. is an independent investment research publisher, offering premium equity reports and dividend reports, as well as commentary across all sectors/companies, a Best Ideas Newsletter (spanning market caps, asset classes), a Dividend Growth Newsletter, modeling tools/products, and more. Independence and integrity remain our core, and we strive to be a champion of the investor. Valuentum is based in the Chicagoland area. Valuentum is not a money manager, broker, or financial advisor. Valuentum is a publisher of financial information. We address a number of questions from both subscribers and visitors to our site.
Apr 19, 2024
Dividend Increases/Decreases for the Week of April 19
Let's take a look at firms raising/lowering their dividends this week.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.